Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leht 1 alates 48 tulemused
Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
[Not applicable]
BACKGROUND
The tumor suppressor p53 (protein expressed from TP53) has been shown to be downregulated in numerous cancers. The p53 protein exerts its tumor suppressive function acting
Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
The present invention relates to a pharmaceutical composition comprising of proline or proline derivatives or their salts, esters, isomers or prodrugs together with an anti-cancer ligand, preferably an antibody directed to a tumour antigen. The invention is also directed
Combination of cis-4-hydroxy-L-proline and N-methyl-cis-4-hydroxy-L-proline for use as a therapeutic agent, in particular in cancer treatment
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
INTRODUCTION
The invention relates to a combination of therapeutic agents, comprising as essential components:
(A) cis-4-hydroxy-L-proline and
(B) N-methyl-cis-4-hydroxy-L-proline, or their pharmacologically compatible derivatives or precursors, for use as a therapeutic agent, particularly for
Aprepitant L-proline solvates--compositions and cocrystals
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The invention relates to a new aprepritant compositions and crystalline compounds containing aprepitant. More particularly, the invention relates to solvated aprepitant L-proline solvate compositions, aprepitant L-proline solvate cocrystals, therapeutic uses of the aprepitant
Aprepitant L-proline composition and cocrystal
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The invention relates to a new aprepitant composition and a crystalline compound containing aprepitant, more particularly, the invention relates to an aprepitant L-proline composition, an aprepitant L-proline cocrystal, therapeutic uses of the aprepitant L-proline or the
Medicines which contain derivatives of proline or hydroxyproline
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Till now chemotherapeutic treatment of cancer, especially carcinomas, is not satisfying as the therapeutic effects are very limited and the side effects are very severe. The latter is due to the fact that highly toxic substances are used, which damage not only the cancer cells but the other cells of
Tumor marker for pancreatic cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This application is a U.S. national stage of International Application No. PCT/JP2008/063235 filed Jul. 24, 2008.
CROSS-REFERENCE OF RELATED APPLICATION
This patent application claims a priority based on a prior Japanese Patent Application, Japanese Patent Application No. 193328/2007 (filing date:
Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FILED OF THE INVENTION
The present invention relates to the use of catechin compounds in combination with other dietary constituents in inhibiting matrix-metalloproteinases. More particularly, the present invention relates to the use of a composition comprising catechin, ascorbic acid, lysine and
Treating cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a U.S. National Stage Application filed under 35 U.S.C. .sctn.371 and claims priority to International Application No. PCT/EP2009/052883, filed Mar. 11, 2009, which application claims priority to Great Britain Application No. 0804496.8,
Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention relates to a nutrient pharmaceutical formulation and its use for the treatment of cancer. More specifically, the present invention relates to polyphenol containing pharmaceutical formulations having an effective amount of polyphenols for the treatment of
Localization and characterization of the Wilms' tumor gene
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FUNDING
Work described herein was funded by the National Institutes of Health, the Medical Research Council of Canada and the National Cancer Institute.
BACKGROUND
Wilms' tumor (WT) is an embryonal malignancy of the kidney which affects approximately 1 in 10,000 infants and young children.
Localization and characterization of the Wilms' tumor gene
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FUNDING
Work described herein was funded by the National Institutes of Health, the Medical Research Council of Canada and the National Cancer Institute.
BACKGROUND
Wilms' tumor (WT) is an embryonal malignancy of the kidney which affects approximately 1 in 10,000 infants and young children.
Localization and characterization of the Wilms' tumor gene
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FUNDING
Work described herein was funded by the National Institutes of Health, the Medical Research Council of Canada and the National Cancer Institute.
BACKGROUND
Wilms' tumor (WT) is an embryonal malignancy of the kidney which affects approximately 1 in 10,000 infants and young children.
Localization and characterization of the Wilms' tumor gene
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Wilm's tumor (WT) is an embryonal malignacy of the kidney which affects approximately 1 in 10,000 infants and young children. Matsunaga, Human Genetics, 57: 231-246 (1981). The molecular basis of Wilms' tumor is not well understood.
A subset of Wilms' tumor cases (approximately 2%) occur
Peptides for the treatment of cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a national phase application under 35 U.S.C. .sctn.371 of International Application No. PCT/EP2014/050330 filed 9 Jan. 2014, which claims priority to European Patent Application No. 13150974.7 filed 11 Jan. 2013. The entire contents of each
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
